BNP Paribas Arbitrage SA Increases Stake in MiMedx Group Inc (MDXG)

BNP Paribas Arbitrage SA grew its holdings in MiMedx Group Inc (NASDAQ:MDXG) by 31.8% in the first quarter, HoldingsChannel reports. The institutional investor owned 57,575 shares of the medical equipment provider’s stock after buying an additional 13,878 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in MiMedx Group were worth $401,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. UBS Asset Management Americas Inc. increased its stake in shares of MiMedx Group by 65.1% in the fourth quarter. UBS Asset Management Americas Inc. now owns 82,979 shares of the medical equipment provider’s stock valued at $1,046,000 after buying an additional 32,718 shares in the last quarter. PEAK6 Investments L.P. acquired a new stake in shares of MiMedx Group in the fourth quarter valued at $983,000. BlackRock Inc. increased its stake in shares of MiMedx Group by 1.1% in the fourth quarter. BlackRock Inc. now owns 13,607,325 shares of the medical equipment provider’s stock valued at $171,588,000 after buying an additional 147,214 shares in the last quarter. State of Wisconsin Investment Board increased its stake in shares of MiMedx Group by 32.0% in the first quarter. State of Wisconsin Investment Board now owns 104,300 shares of the medical equipment provider’s stock valued at $727,000 after buying an additional 25,300 shares in the last quarter. Finally, Teachers Advisors LLC increased its stake in shares of MiMedx Group by 35.3% in the fourth quarter. Teachers Advisors LLC now owns 315,360 shares of the medical equipment provider’s stock valued at $3,977,000 after buying an additional 82,229 shares in the last quarter. Institutional investors own 75.30% of the company’s stock.

MDXG has been the topic of several recent research reports. BidaskClub cut MiMedx Group from a “sell” rating to a “strong sell” rating in a report on Saturday, June 16th. ValuEngine cut MiMedx Group from a “sell” rating to a “strong sell” rating in a report on Wednesday, May 2nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of MiMedx Group in a report on Thursday, March 15th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $16.00.

MiMedx Group stock opened at $5.86 on Thursday. The stock has a market capitalization of $647.33 million, a P/E ratio of 27.76, a PEG ratio of 0.76 and a beta of 1.53. MiMedx Group Inc has a 12-month low of $4.95 and a 12-month high of $18.25.

MiMedx Group Company Profile

MiMedx Group, Inc, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.

Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group Inc (NASDAQ:MDXG).

Institutional Ownership by Quarter for MiMedx Group (NASDAQ:MDXG)

Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply